08:33 AM EDT, 05/14/2025 (MT Newswires) -- Quoin Pharmaceuticals ( QNRX ) said Wednesday preliminary results from a study evaluating its therapy candidate QRX003 in a pediatric peeling skin syndrome patient showed 'clear evidence of skin healing' in the area treated over 12 weeks.

The company reported progress across multiple endpoints, including that QRX003 has been well tolerated with no adverse effects. Quoin added that similar safety and tolerability have been seen in its separate trials studying the treatment in patients with Netherton Syndrome.

The company plans to enroll additional pediatric subjects globally and said QRX003 may be the first therapy approved for peeling skin syndrome, if development continues to progress successfully.

Shares of the company were up nearly 40% in recent Wednesday premarket activity.